eTable 2. The effect of COCs on cancer risk.
| Carcinoma | Royal College of General Practitioners—Study 2007*1 RR (95% CI) | Oxford Family Planning Association Study 2006*2 RR (95% CI) |
| Colorectal | 0.72 (0.58–0.90) | 0.8 (0.6–1.2) |
| Hepatobiliary | 0.55 (0.26–1.17) | No data |
| Lung | 1.05 (0.82–1.35) | 1.4 (0.9–2.1) |
| Melanoma | 0.92 (0.65–1.29) | 0.8 (0.5–1.2) |
| Breast | 0.98 (0.87–1.10) | 1.0 (0.8–1.1) |
| Cervical | 1.33 (0.92–1.94) | 4.2 (1.8–12.0) |
| Endometrial and uterine body | 0.58 (0.42–0.79) | 0.3 (0.2–0.6) |
| Ovar | 0.54 (0.40–0.71) | 0.5 (0.3–0.7) |
| CNS/pituitary | 1.34 (0.73–2.47) | No data |
| Gastrooesophageal | No data | 0.6 (0.3–1.3) |
| Renal/bladder | No data | 0.8 (0.5–1.5) |
| Lymphoma/leukemia | No data | 1.1 (0.7–1.6) |
| All cancers | 0.88 (0.83–0.94) | No data |